News | September 23, 2007

Cardiologists Implant First Stentys Bifurcated DES

September 24, 2007 - Stentys announced that its drug-eluting bifurcated stent for treatment of blocked coronary artery bifurcations was implanted in a patient, marking the first human implantation of the stent.

The implant was completed in reportedly routine interventional time, and the patient was released from the ICU within hours of the implantation of the Stentys bifurcated stent and was discharged from the hospital shortly after the procedure.

The patent-pending innovation of Stentys' bifurcated stent is that the stent-opening for the side branch can be created reportedly anywhere in the stent after it is implanted in the vessel. The Stentys procedure is performed in three steps. The stent is implanted in the main vessel with an approximate positioning, like a standard stent. The cardiologist chooses the optimal location for the side branch opening by inserting a balloon through the stent mesh, which is a cath lab-standard procedure. Finally, the balloon inflation disconnects the mesh and creates the opening. Stentys' self-expanding property reportedly allows the in situ modeling of the stent to fit the patient’s unique arterial anatomy.

For more information: www.stentys.com


Related Content

News | Stents Drug Eluting

July 2, 2024 — Biotronik announced the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro ...

Home July 02, 2024
Home
News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
Subscribe Now